

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect





**Psychiatry Research** 

journal homepage: www.elsevier.com/locate/psychres

# Long term impact of Covid-19 infection on sleep and mental health: A cross-sectional study

Gellan K. Ahmed<sup>a,b,\*</sup>, Eman M. Khedr<sup>a</sup>, Dina A. Hamad<sup>c</sup>, Taghreed S. Meshref<sup>c</sup>, Mustafa M. Hashem<sup>a</sup>, Mai M. Aly<sup>d</sup>

<sup>a</sup> Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt

<sup>b</sup> Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, United Kingdom

<sup>c</sup> Critical Care unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt

<sup>d</sup> Clinical Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt

ARTICLE INFO

Keywords: COVID-19 Depression Anxiety Insomnia Mental health

# ABSTRACT

The long-term impact of the COVID-19 infection on mental health in people and its relation to the severity is unclear. We aimed to study the long-term effect of post-COVID-19 disease on sleep and mental health and to detect possible relationship between severity of COVID-19 at onset and sleep and mental illness. We enrolled 182 participants 6 months post COVID-19 infection and grouped into non-severe(101),severe(60) and critical(20) according to according to WHO guidance. All participants were assessed using Pittsburgh Sleep Quality Index ", Post traumatic stress disorder (PTSD) Checklist for DSM-5, and Symptom Checklist90 test. Only 8.8% had no psychiatric symptoms while 91.2% had psychiatric symptoms as follow (poor sleep (64.8%), PTSD (28.6%), somatization (41.8%), obsessive-compulsive (OCD) (19.8%), depression (11.5%), anxiety (28%), phobic-anxiety (24.2%), psychoticism (17.6%)). Diabetes, oxygen support or mechanically ventilated were a risk for sleep impairment, while high Neutrophil/lymphocyte ratio(**NLR**) was the only risk factor for PTSD. Other psychiatric illnesses had several risk factors: being female, diabetes, oxygen support or mechanically ventilated. Abnormal sleep, somatization and anxiety are the most common mental illnesses in Post-Covid19. The critical group is common associated with PTSD, anxiety, and psychosis. Being female, diabetic, having oxygen support or mechanically ventilated, and high NLR level are more vulnerable for mental illness in post COVID19.

#### 1. Introduction

Covid-19 was the first pandemic infectious disease in the 21st century (Xie et al., 2020). The virus spreads rapidly worldwide by travellers, with more than 72 million cases and more than 1 million deaths world-wide by December 14, 2020(Worldometer COVID-19 Coronavirus Pandemic, 2020).

However, the impact of COVID-19 on mental health have been raised since its early stages (Gellan et al., 2021; Xiang et al., 2020). After some pandemics, psychological consequences have been reported as following severe acute respiratory syndrome (SARS), Ebola, and H1N1(Li and Wang, 2020; Pan et al., 2020; Taquet et al., 2021; Xiang et al., 2020). A meta-analysis estimated the incidence of psychiatric disorders after SARS and Middle East respiratory syndrome outbreaks suggested that coronavirus infections can lead to delirium, anxiety, depression, manic symptoms, poor memory, and insomnia (Rogers et al., 2020) Various psychological diseases have been predicted to occur in COVID-19 survivors, as they faced significant challenges to survive fear from infecting other members, probability of death at any time, and fear from future repeated infection in addition to physical stress from the disease itself. There are biological factors of mental disorders related to COVID-19 infection that could also be implicated as the inflammation process involved in many psychiatric disorders (Wang et al., 2021).

A questionable point in the relation between COVID-19 infection and psychological disorders is whether SARS-Co 19 infection increases liability to psychological disorders, or the reverse theory is more accepted. Recent metanalysis study found that there was increased risk of depression and anxiety in COVID-19 patients compared to other inpatients. This study also recommended further assessment of the longterm mental health effect of COVID-19 infections (Deng et al., 2021). In addition, a previous large study evaluated psychological disorders within 3 months after diagnosis of COVID-19 infection. It found that the COVID-19 survivors had a significantly higher rate of psychiatric

\* Corresponding author at: Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt. *E-mail address:* gillankaram@aun.edu.eg (G.K. Ahmed).

https://doi.org/10.1016/j.psychres.2021.114243

Received 7 May 2021; Received in revised form 3 October 2021; Accepted 10 October 2021 Available online 12 October 2021 0165-1781/© 2021 Elsevier B.V. All rights reserved.

Abbrevi	ation
SCL 90	symptom Checklist 90
PCL-5	post-traumatic stress disorder (PTSD)
PSQI	Pittsburgh Sleep Quality Index
TLC	Complete blood count; total leucocyte count
RBC	red blood cells
HB	haemoglobin level
ALC	absolute lymphocyte count
AMC	absolute monocyte count
ANC	absolute neutrophil count
NLR	Neutrophil/lymphocyte ratio
CRP	(C-reactive protein)
MSCT	Multi-slice computed tomography

disorders, dementia, and insomnia; moreover, a previous psychiatric illness was independently associated with an increased risk of being diagnosed with COVID-19 (Taquet et al., 2021).

In current study, we aimed to evaluate the long-term impact of COVID-19 and its risk factors on sleep, and mental health, and to detect the relationship between mental disorders and COVID -19 severity after six months of infection.

### 2. Methods

# 2.1. Participants

A cross-sectional study enrolled 300 participants who admitted at Assiut university hospital after their diagnosed with Covid-19 from 1st of July to 1st of September 2020 by using real-time PCR methods in throat swab specimens (World Health Organization, 2020). All patients were asked to come to the outpatient clinics of Assiut University hospital, six months after the discharge for follow up. Follow up of those patients started from 1st of January 2021 and ended at 1st of Mach, 2021. Out of 300 patients, only 182 patients were eligible according to inclusion and exclusion criteria as follow: age 18 years old or above who had documented diagnosis of Covid-19 according to WHO guidance. Patients with a history of psychiatric disorders before diagnosis with COVID-19 were excluded.

Eligible participants were classified into 3 groups at the time of diagnosis according to criteria reported by (Wu et al., 2020):

- Critical (A): including those with respiratory failure that requires artificial ventilation, shock, or any end-organ damage.
- (2) Severe (B): including those with a ratio of arterial partial oxygen pressure to inspired oxygen fraction (PaO<sub>2</sub>/FiO<sub>2</sub>) <300 mmHg, respiratory rate >30 breaths per minute, lung infiltrates >50% or patients with SpO2 <94% in room air.</p>
- (3) Non-severe (C): all remaining patients who did not meet the criteria for groups A and B.

The critical group: included 20 patients (8 females and 12 males) with mean age was  $59\pm11.462$ . The severe group: included 60 patients (24 females and 37 males) with mean age was  $54.98\pm15.05$ . The non-severe group: included 101 patients (52 females and 49 males) with mean age was  $38.88\pm16.07$ .

#### 2.2. Ethical consideration

The Faculty of Medicine's institutional review board, Assiut University, granted ethical approval for the study and registered it as a clinical trial. All participants had written informed consent to take part in the research. They were assured of data protection and were informed

that data in anonymized form would be available. This study was carried out following the latest version of the Declaration of Helsinki.

2.3. Procedure

2.3.1. Data on hospital admission

Each patient was subjected to the following sociodemographic and clinical data. It included: age, sex, marital status, educational level, history of smoking, diabetes mellitus (DM), hypertension (HTN), and cardiovascular disease (CVD), the severity of COVID 19, duration of hospital admission, oxygen supply, and need for mechanical ventilation.

*Laboratory data.* Complete blood count; total leucocyte count (TLC), red blood cells (RBC), haemoglobin level (HB), absolute lymphocyte count (ALC), absolute monocyte count (AMC), absolute neutrophil count (ANC), Neutrophil/lymphocyte ratio (NLR =ANC/ALC). CRP (C-reactive protein), serum ferritin, and p-dimer. All collected laboratory results are at the time of diagnosis.

*Imaging data.* Multi-slice computed tomography (MSCT) of the chest of the patients, which was classified into either specific finding suggestive to COVID-19 infection present or not as bilateral or unilateral multifocal ground-glass opacities that classically predominate in the peripheral, posterior, and basal part of the lungs or other less specific findings.

2.3.2. During follow up visit (six month after COVID-19 infection) each patient patients were subjected to a full psychiatric and medical assessment at the beginning of the study then had the following

*Pittsburgh sleep quality index "PSQI" (Buysse et al., 1989).* It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a "global" score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, the higher the score, the worse the sleep quality. Each question assesses a different aspect of sleep problems.

Post traumatic disorder checklist for DSM-5 (PCL-5): (Weathers et al., 2013): "PCL-5". It is a 20 item self-report and measures the symptoms of post-traumatic stress disorder (PTSD) by using criteria of Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5). The cut off used for the PCL5 is 33 or higher to efficient for diagnosing PTSD (Bovin et al., 2016).

*Symptom checklist 90 "SCL 90" (Derogatis, 1983).* It is a 90-item questionnaire used to assess psychological problems. Each item is scored on a scale from 0 to 4 based on how much an individual was bothered by each item. It has 9 subscales: (Somatization, Obsessive-compulsive, Interpersonal sensibility, Depression, Anxiety, Anger-hostility, Phobic-anxiety, Paranoid ideation, Psychoticism).

#### 2.4. Statistical analysis

SPSS was used to conduct the analysis (version 26 IBM, Armonk, NY, USA). The mean and standard deviation of continuous data were measured, and the frequency of nominal data was measured (percent). The three study groups' nominal data were compared using the chi-square test, while the three groups' mean was compared using the ANOVA. Multivariate logistic regression was done to identified risk factors for PCL-5, PSQI, and 7 major psychiatric disorders regarding SCL90. P<0.05 was considered statistically significant.

#### 3. Results

#### 3.1. Baseline assessment

### 3.1.1. Sociodemographic and clinical data

The mean age of was significantly higher in the critical group and the severe group than the non-severe group ( $59\pm11.462$ ,  $54.98\pm15.05$ ,  $38.88\pm16.07$ , respectively) (P < 0.0001).

Duration of admission was significantly longer (more than 12 days) in the critical (65%) and severe groups (62.3%) in comparison to the non-severe group (30.7%). Hypertension (35%) and cardiovascular disease (15%) were significantly more in the critical group (P = 0.0001). On the other side diabetes (32.8) was more in the severe group (P = 0.0001). Details illustrated in Table 1.

# 3.1.2. Laboratory and imaging finding

The laboratory examination showed that the mean haemoglobin level was significantly higher in the non-severe group  $(12.86\pm2.16)$  then the severe group  $(11.67\pm2.58)$  then the critical group  $(11.26\pm2.38)$  (P = 0.001). White blood cell indices, namely TLC  $(10.25\pm3.57 \text{ vs. } 7.83\pm5.86 \text{ vs. } 5.41\pm2.78; P<0.0001$ ), ANC  $(8.04\pm3.39 \text{ vs. } 5.05\pm5.22 \text{ vs. } 2.89\pm2.17; P < 0.0001$ ) and NLR  $(5.26\pm2.76 \text{ vs. } 3.45\pm3.73 \text{ vs. } 1.71\pm1.13; P<0.0001)$  were significantly higher in a critical group vs. severe vs. non-severe group, respectively.

Regarding the inflammatory markers, ferritin and D-dimer were significantly higher in the critical compared to the severe and non-severe patients (P = 0.002, P < 0.0001, respectively). About 70% of severe patients required oxygen aid (P < 0.0001), while 40% of the critical group required mechanical ventilation (P < 0.0001).

# 3.2. Sleep disturbance and mental illness six-month post COVID-19 infection

Out of 182 only 16 participants (8.8%) did not have any sleep or psychiatric problem. About 118 participants (64.8%) had poor sleep quality, while 52 participants (28.6%) had Probable PTSD response. The highest percentage of symptomatology was somatization (41.8%), followed by anxiety (28%), anger-hostility, phobic-anxiety (24.2%), obsessive-compulsive was (19.8%), interpersonal sensibility was (0.5%), depression was (11.5%), anger-hostility was (15.9%), paranoid ideation was (10.4%), and psychoticism was (17.6%).

# 3.2.1. Relation between the severity of COVID-19 infection at base line and sleep disturbance and mental illness

In Table 2, there was no statistically significant difference among the studied groups regarding sleep quality measured by PSQI, post-traumatic stress disorder measured by PCL-5, and somatization and obsessive-compulsive subscales measured by SCL90. Poor quality of sleep formed the most significant proportion among all studied groups while the higher percentages of the probable PTSD response were in the critical group (45%).

In comparison within each group, the non-severe group and severe group, the low percentages of abnormal response were observed in all subscales of SCL90 except somatization relative to borderline or normal responses. While the critical group showed abnormal response represented the highest proportion of anxiety (40%) relative to borderline or normal responses.

# 3.3. Identification of possible risk factors of mental illness in post COVID-19 patients

Multiple risk factors that affected sleep quality and PTSD were studied in multivariate regression analysis were shown in Table 3. Levels of education [elementary school (P = 0.013), and high school (P = 0.013)] were less vulnerable for sleep quality disorders while being just read and write (P = 0.001), diabetes (P = 0.035), severe group (P = 0.035)

# Table 1

	Total of cases(N	Non- severe	Severe group	Critical group(N	P-value
	= 182)	group(N = 101)	(N=61)	= 20)	
Ago in Voore	46.40		E4 08 1	E0	<0.0001
Age in Years (mean ±SD)	$46.49 \pm 17.4$	$\begin{array}{c} 38.88 \pm \\ 16.07 \end{array}$	$54.98 \pm 15.05$	$59 \pm 11.462$	<0.0001
Gender	17.4	10.07	15.05	11.402	
Male	84	49	37	12 (60%)	0.273
indic .	(46.2%)	(48.5%)	(60.7%)	12 (0070)	0.270
Female	98	52	24	8 (40%)	
	(53.8%)	(51.5%)	(39.3%)	- ( ) - )	
Marital status		. ,	. ,		
Single	36	22	12	2 (10%)	0.038
0	(19.8%)	(21.8%)	(19.7%)		
Married	128	64	48	16 (80%)	
	(70.3%)	(63.4%)	(78.7%)		
Divorce	10	10	0(0%)	0 (0%)	
	(5.5%)	(9.9%)			
Widow	8 (4.4%)	5 (5%)	1 (1.6%)	2 (10%)	
Education					
Reading and	28	17	8	3 (15%)	0.503
writing	(15.4%)	(16.8%)	(13.1%)		
Elementary	12	8 (7.9%)	3 (4.9%)	1 (5%)	
school	(6.6%)				
High school	16	12	4 (6.6%)	0 (0%)	
	(8.8%)	(11.9%)			
Higher education	126	64	46	16 (80%)	
	(69.2%)	(63.4%)	(75.4%)		
Smoking	-				
smoker	56	37	13	6 (30%)	<0.000
	(30.8%)	(36.6%)	(21.3%)		
Non-smoker	126	64	48	14 (60%)	
	(69.2%)	(63.4%)	(78.7%)		
Duration of	12.24 $\pm$	$11.89 \pm$	$12.25 \pm$	$14 \pm 3$	<0.000
admission	1.9	1.44	1.82		
More than 12 days	82	31	38	13 (65%)	0.025
Loss than 10 days	(45.1%)	(30.7%)	(62.3%)	7 (250/)	
Less than 12 days	100	70	23	7 (35%)	
Comoubidition	(54.9%)	(69.3%)	(37.7%)		
Comorbidities DM	28	4 (4%)	20	4 (20%)	<0.000
HTN	28 (15.4%)	4 (4%) 3 (3%)	(32.8%)	4 (20%) 7 (35%)	<0.000
CVD	(13.4%)	3 (3%)	(32.8%) 6 (9.9%)	3 (15%)	<0.000
CVD	(8.8%)	3 (370)	2 (3.3%)	3 (13%)	<b>\0.000</b>
	8 (4.4%)		2 (0.070)		
Laboratory	0 (1170)				
(CBC)					
(		10.06	11.67 $\pm$	11.26 $\pm$	
HB (g/dL)	$12.29 \pm$				0.001
HB (g/dL)	$12.29 \pm 2.41$	$12.86 \pm 2.16$	2.58		0.001
-	2.41	2.16	2.58 215.06	2.38	
HB (g/dL) Platelets (× 10 <sup>9</sup> / L)			215.06	2.38 252.85	<b>0.001</b> 0.242
Platelets (× 10 <sup>9</sup> /	2.41 228.84	2.16 232.42		2.38	0.242
Platelets (× 10 <sup>9</sup> / L)	$\begin{array}{c} \textbf{2.41} \\ \textbf{228.84} \\ \pm \textbf{92.62} \end{array}$	$\begin{array}{c} 2.16 \\ 232.42 \\ \pm \ 92.05 \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \end{array}$	$2.38 \\ 252.85 \\ \pm 123.5$	0.242
Platelets (× 10 <sup>9</sup> / L)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \ \pm \end{array}$	$\begin{array}{c} 2.16 \\ 232.42 \\ \pm \ 92.05 \\ 5.41 \ \pm \end{array}$	$215.06 \pm 80.74 \\ 7.83 \pm$	$\begin{array}{c} 2.38 \\ 252.85 \\ \pm \ 123.5 \\ 10.25 \ \pm \end{array}$	0.242 < <b>0.000</b> 2
Platelets (× $10^9$ / L) TLC (× $10^9$ /L)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \ \pm \\ 4.4 \end{array}$	$\begin{array}{c} 2.16 \\ 232.42 \\ \pm \ 92.05 \\ 5.41 \ \pm \\ 2.78 \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \end{array}$	$\begin{array}{c} 2.38 \\ 252.85 \\ \pm \ 123.5 \\ 10.25 \ \pm \\ 3.57 \end{array}$	0.242 < <b>0.000</b> 2
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ )	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \ \pm \\ 4.4 \\ 4.17 \ \pm \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\end{array}$	0.242 < <b>0.000</b> 2
Platelets (× $10^9$ / L) TLC (× $10^9$ /L)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \ \pm \\ 4.4 \\ 4.17 \ \pm \\ 3.94 \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41 \\ \pm\\ 2.78\\ 2.89 \\ \pm\\ 2.17 \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39 \end{array}$	0.242 <0.0002 <0.0002
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ )	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41 \pm\\ 2.78\\ 2.89 \pm\\ 2.17\\ 1.79 \pm\\ \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \pm \\ 5.86 \\ 5.05 \pm \\ 5.22 \\ 1.93 \pm \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39\\ 1.61\ \pm\end{array}$	0.242 <0.0002 <0.0002
Platelets (× $10^{9}/$ L) TLC (× $10^{9}/$ L) ANC (× $10^{9}/$ L) ALC (× $10^{9}/$ L)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41 \\ \pm\\ 2.78\\ 2.89 \\ \pm\\ 2.17\\ 1.79 \\ \pm\\ 0.73\end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \pm \\ 5.86 \\ 5.05 \pm \\ 5.22 \\ 1.93 \pm \\ 1.46 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39\\ 1.61\ \pm\\ 0.43\\ \end{array}$	0.242 < <b>0.000</b> < <b>0.000</b> 0.444
Platelets (× 10 <sup>9</sup> / L) TLC (× 10 <sup>9</sup> /L) ANC (× 10 <sup>9</sup> /L) ALC (× 10 <sup>9</sup> /L) AMC (× 10 <sup>9</sup> /L)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\\ \pm\\ 3.57\\ 8.04\\ \pm\\ 3.39\\ 1.61\\ \pm\\ 0.43\\ 0.58\\ \pm\end{array}$	0.242 < <b>0.000</b> < <b>0.000</b> 0.444 0.424
Platelets (× 10 <sup>9</sup> /L) TLC (× 10 <sup>9</sup> /L) ANC (× 10 <sup>9</sup> /L) ALC (× 10 <sup>9</sup> /L) AMC (× 10 <sup>9</sup> /L)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\\ \pm\\ 3.57\\ 8.04\\ \pm\\ 3.39\\ 1.61\\ \pm\\ 0.43\\ 0.58\\ \pm\\ 0.23\\ \end{array}$	0.242 < <b>0.000</b> < <b>0.000</b> 0.444 0.424
Platelets (× 10 <sup>9</sup> / L) TLC (× 10 <sup>9</sup> /L) ANC (× 10 <sup>9</sup> /L) ALC (× 10 <sup>9</sup> /L) AMC (× 10 <sup>9</sup> /L) NLR	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \\ 3.45 \ \pm \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ \end{array}$	0.242 < <b>0.000</b> < <b>0.000</b> 0.444 0.424
Platelets (× 10 <sup>9</sup> / L) TLC (× 10 <sup>9</sup> /L) ANC (× 10 <sup>9</sup> /L) ALC (× 10 <sup>9</sup> /L) AMC (× 10 <sup>9</sup> /L) NLR	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \\ 3.45 \ \pm \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ \end{array}$	0.242 < <b>0.000</b> < <b>0.000</b> 0.444 0.424
Platelets (× 10 <sup>9</sup> / L) TLC (× 10 <sup>9</sup> /L) ANC (× 10 <sup>9</sup> /L) ALC (× 10 <sup>9</sup> /L) AMC (× 10 <sup>9</sup> /L) NLR Inflammatory markers	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \\ 3.45 \ \pm \\ 3.73 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39\\ 1.61\ \pm\\ 0.43\\ 0.58\ \pm\\ 0.23\\ 5.26\ \pm\\ 2.76\\ \end{array}$	0.242 < <b>0.000</b> < <b>0.000</b> 0.444 0.424
Platelets (× $10^9/L$ ) TLC (× $10^9/L$ ) ANC (× $10^9/L$ ) ALC (× $10^9/L$ ) AMC (× $10^9/L$ ) NLR Inflammatory markers CRP (mg/l)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \\ 3.45 \ \pm \\ 3.73 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002 0.298
Platelets (× 10 <sup>9</sup> / L) TLC (× 10 <sup>9</sup> /L) ANC (× 10 <sup>9</sup> /L) ALC (× 10 <sup>9</sup> /L) AMC (× 10 <sup>9</sup> /L) NLR Inflammatory markers	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \\ 3.45 \ \pm \\ 3.73 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002
Platelets (× $10^9/L$ ) TLC (× $10^9/L$ ) ANC (× $10^9/L$ ) ALC (× $10^9/L$ ) AMC (× $10^9/L$ ) NLR Inflammatory markers CRP (mg/l)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0001 0.444 0.424 <0.0001 0.298
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06 \\ \pm \ 80.74 \\ 7.83 \ \pm \\ 5.86 \\ 5.05 \ \pm \\ 5.22 \\ 1.93 \ \pm \\ 1.46 \\ 0.57 \ \pm \\ 0.35 \\ 3.45 \ \pm \\ 3.73 \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002 0.298
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml) D- dimer (mcg/	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$ $\begin{array}{c} 52.07 \\ \pm \\ 103.91 \\ 368.76 \\ \pm \\ 449.53 \\ 1.53 \\ \pm \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39\\ 1.61\ \pm\\ 0.43\\ 0.58\ \pm\\ 0.23\\ 5.26\ \pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002 0.298 0.002
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml) D- dimer (mcg/ ml)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 1.71 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39\\ 1.61\ \pm\\ 0.43\\ 0.58\ \pm\\ 0.23\\ 5.26\ \pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002 0.298 0.002
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml) D- dimer (mcg/ ml) MSCT chest	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$ $\begin{array}{c} 52.07 \\ \pm \\ 103.91 \\ 368.76 \\ \pm \ 449.53 \\ 1.53 \\ \pm \\ 1.54 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002 0.298 0.002 <0.0002
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml) D- dimer (mcg/ ml)	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\ \pm\\ 3.57\\ 8.04\ \pm\\ 3.39\\ 1.61\ \pm\\ 0.43\\ 0.58\ \pm\\ 0.23\\ 5.26\ \pm\\ 2.76\\ \end{array}$	0.242 <0.0002 0.444 0.424 <0.0002 0.298 0.002
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml) D- dimer (mcg/ ml) MSCT chest No affection	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 4.17 \\ \pm \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0001 0.444 0.424 <0.0001 0.298 0.002 <0.0001
Platelets (× $10^{9}/L$ ) TLC (× $10^{9}/L$ ) ANC (× $10^{9}/L$ ) ALC (× $10^{9}/L$ ) AMC (× $10^{9}/L$ ) NLR Inflammatory markers CRP (mg/l) Ferritin (mcg/ml) D- dimer (mcg/ ml) MSCT chest	$\begin{array}{c} 2.41 \\ 228.84 \\ \pm \ 92.62 \\ 6.75 \\ \pm \\ 4.4 \\ 3.94 \\ 1.81 \\ \pm \\ 1.02 \\ 0.78 \\ \pm \\ 1.88 \\ 2.68 \\ \pm \\ 2.75 \\ \end{array}$	$\begin{array}{c} 2.16\\ 232.42\\ \pm \ 92.05\\ 5.41\ \pm\\ 2.78\\ 2.89\ \pm\\ 2.17\\ 1.79\ \pm\\ 0.73\\ 0.94\ \pm\\ 2.5\\ 1.71\ \pm\\ 1.13\\ \end{array}$	$\begin{array}{c} 215.06\\ \pm\ 80.74\\ 7.83\ \pm\\ 5.86\\ 5.05\ \pm\\ 5.22\\ 1.93\ \pm\\ 1.46\\ 0.57\ \pm\\ 0.35\\ 3.45\ \pm\\ 3.73\\ \end{array}$	$\begin{array}{c} 2.38\\ 252.85\\ \pm\ 123.5\\ 10.25\pm\\ 3.57\\ 8.04\pm\\ 3.39\\ 1.61\pm\\ 0.43\\ 0.58\pm\\ 0.23\\ 5.26\pm\\ 2.76\\ \end{array}$	0.242 <0.0001 0.444 0.424 <0.0001 0.298 0.002 <0.0001

#### Table 1 (continued)

	Total of cases(N = 182)	Non- severe group(N = 101)	Severe group (N = 61)	Critical group(N = 20)	<i>P</i> -value
Oxygen support Any oxygen aids other than mechanical ventilation n	68 (37.4%)	12 (11.9%)	43 (70.5%)	13 (65%)	<0.0001
(%) Mechanical ventilation n (%)	8 (4.4%)	0 (0%)	0 (0%)	8 (40%)	<0.0001

ALC: Absolute Lymphocytic Count, AMC: Absolute Monocyte Count, ANC: Absolute neutrophilic count, CBC: Complete Blood Count, CRP: C reactive protein, CVD: Cerebro-Vascular disease, DM: Diabetes, HB: Hemoglobin, HTN: Hypertension, MSCT: Multi-Slice Computerized Tomography, NLR: Neutrophil Lymphocyte Ratio, TLC: Total Leucocyte Count.

Chi test and ANOVA test used for statistical Analysis (significant P value <0.05).

0.001), and use of oxygen aids (P = 0.001) were independent risk factors for sleep quality impairment. In contrast, just read and write (P = 0.017) and have high NLR (P = 0.031) were a significant risk for PTSD.

In **Table 4**, The multivariate logistic regression module shown risk factors on somatization, anxiety, depression, and obsessive-compulsive disorder of the studied group. Surprisingly, none of the studied risk factors were associated with somatization disorder. Adults less than 60 years were less vulnerable for anxiety while being female (P = 0.004) and had non-severe presentations were independent risk factors for anxiety.

Patients with age range from 18 to 30 years (P = 0.005) were less risky for depression while being diabetic (P = 0.039) and had low Hb levels (P = 0.008) were more vulnerable for depression.

Regarding obsession, adults less than 60 years were decreased risk of disorder but being smokers was increased risk for that disorder (P = 0.028).

On the other hand, females, patients who were on oxygen support, were mechanically ventilated, just read and write (P = 0.03), diabetics, non-severe, and severe groups of patients were at higher risk of phobicanxiety disorder; while adults less than 60 years were at lower risk of phobic anxiety. According to paranoid ideation, females (P = 0.023), being just read and write (P = 0.01), had non-severe (P = 0.003) or severe groups (P = 0.009) were more likely to develop. However, adults less than 60 years, single or married patients had reduced risk for paranoid ideation. In contrast, females, diabetics, and just read and write were independent predictors for psychosis; detailed analysis is shown in Table 5.

#### 4. Discussion

In relation to the COVID-19 pandemic, many studies investigated its psychological impact on the general population (Li and Wang, 2020), newly recovered patients (Pan et al., 2020), and within 3 months post COVID-19 diagnosis (Taquet et al., 2021). Previous research found that psychiatric morbidities can persist for over 2 years in patients previously infected by SARS (Mak et al., 2009). So, to the best of our knowledge, this study is the first study that addressed the long-term impact of COVID-19 infection and its risk factors on sleep and mental health and their relation to severity, comorbidities, and other risk factors.

In current study, we reported that only 8.8% of participants had no sleep disturbance or psychiatric symptoms, while 91.2% had psychiatric symptoms as follow: poor sleep (64.8%), PTSD (28.6%), somatization (41.8%), obsessive-compulsive (19.8%), depression (11.5%), anxiety (28%), phobic-anxiety (24.2%), psychoticism (17.6%).

During surge of COVID-19 pandemic, an Egyptian study conducted on general population and health care workers reported that incidence Table 2

Mental health illness in the studied population 6 months after recovery.

Mental health illn		uuleu populat			-
	Total of cases	Non- severe	Severe group	Critical group	P- value
	( <i>N</i> =	group	(N = 61)	(N = 20)	
BEOI	182)	(N = 101)			
<b>PSQI</b> Good quality of	64	36 (35.6%)	21	7 (35%)	0.988
sleep	(35.2%)	00 (00.070)	(34.4%)	, (0070)	01900
Poor quality of	118	65 (64.4%)	40	13 (65%)	
sleep	(64.8%)		(65.6%)		
PCL-5 No PTSD	130	75 (74.3%)	44	11 (55%)	0.217
NO F ISD	(71.4%)	73 (74.370)	(72.1%)	11 (3370)	0.217
Probable PTSD	52	26 (25.7%)	17	9 (45%)	
	(28.6%)		(27.9%)		
Somatization Normal	50	20 (22 70/)	16	7 (250/)	0.006
Normai	52 (28.6%)	29 (28.7%)	16 (26.2%)	7 (35%)	0.026
Borderline	54	25 (24.8%)	18	11 (55%)	
	(29.7%)		(29.5%)		
Abnormal	76	47 (46.5%)	27	2 (10%)	
Obsessive-comp	(41.8%)		(44.3%)		
Normal	94	53 (52.5%)	31	10 (50%)	0.0001
Tiorman	(51.6%)	00 (021070)	(50.8%)	10 (0070)	010001
Borderline	52	17 (16.8%)	26	9 (45%)	
	(28.6%)		(42.6%)		
Abnormal	36 (19.8%)	31 (30.7%)	4 (6.6%)	1(5%)	
Interpersonal se					
Normal	142	72 (71.3%)	54	16 (80%)	0.138
	(78%)		(88.5%)		
Borderline	39	28 (27.7%)	7 (11.5%)	4 (20%)	
Abnormal	(21.4%)	1 (1%)	0(0%)	0 (0%)	
Depression	1 (0.5%)	1 (1%)	0(0%)	0 (0%)	
Normal	114	59 (58.4%)	42	13 (65%)	0.764
	(62.6%)		(68.9%)		
Borderline	47	29 (28.7%)	13	5 (25%)	
Abnormal	(25.8%) 21	13 (12.9%)	(21.3%) 6 (9.8%)	2 (10%)	
Abhorman	(11.5%)	10 (12.970)	0 (9.070)	2 (10/0)	
Anxiety					
Normal	71 (39%)	41 (40.6%)	25 (41%)	5 (25%)	0.143
Borderline Abnormal	60 (33%)	28 (27.7%)	25 (41%)	7 (35%)	
Anger-hostility	51 (28%)	32 (31.7%)	11 (18%)	8 (40%)	
Normal	108	56 (55.4%)	40	12 (60%)	0.250
	(59.3%)		(65.6%)		
Borderline	45	24 (23.8%)	14 (23%)	7 (35%)	
Abnormal	(24.7%) 29	21 (20.8%)	7 (11.5%)	1 (5%)	
Abiorinai	(15.9%)	21 (20.070)	/(11.370)	1 (370)	
Phobic-anxiety	. ,				
Normal	91 (50%)	49(48.5%)	34	8 (40%)	0.096
Doudoulino	47	21(20,00/)	(55.7%)	0 (400/)	
Borderline	47 (25.8%)	21(20.8%)	81 (29.5%)	8 (40%)	
Abnormal	44	31(30.7%)	9 (14.8%)	4 (20%)	
	(24.2%)				
Paranoid ideatio					
Normal	117	64(63.4%)	44 (72,104)	9 (45%)	0.064
Borderline	(64.3%) 46	24(23.8%)	(72.1%) 12	10 (50%)	
	(25.3%)	(_3,0,0)	(19.7%)	(30,0)	
Abnormal	19	13(12.9%)	5 (8.2%)	1 (5%)	
Densha i	(10.4%)				
<b>Psychosis</b> Normal	103	53(52.5%)	42	8 (40%)	0.053
	(56.6%)	00(02.070)	42 (68.9%)	0 (10/0)	0.000
Borderline	47	29(28.7%)	13	5 (25%)	
	(25.8%)	10/20 533	(21.3%)	B (050)	
Abnormal	32 (17.6%)	19(18.8%)	6 (9.8%)	7 (35%)	
	(17.6%)				

**PCL-5:** Post traumatic Stress Disorder Checklist. **PSQI:** Pittsburg Sleep Quality Index.

Chi test and ANOVA test used for statistical Analysis (significant *P* value <0.05).

#### Table 3

Multivariate logistic regressions assessing the association between risk factors of sleep impairment and PTSD in COVID-19 patients.

Variable	Sleep Qualit	y Impairment	PTSD		
	Odds ratio	P value	Odds ratio	P value	
Gender					
Female	1.22	0.68	0.59	0.30	
Age (years) <sup>1</sup>					
18 - 30	0.47	0.23	0.53	0.30	
31 -60	1.58	0.37	1.03	0.94	
Marital status <sup>2</sup>					
Single	1.29	0.77	0.74	0.72	
Married	1.17	0.84	0.23	0.07	
Divorce			2.48	0.41	
Education <sup>3</sup>					
Reading and writing	1.18	0.001	1.12	0.017	
Elementary school	0.11	0.013	0.82	0.80	
High school	0.11	0.013	0.26	0.07	
Smoking state	0.68	0.43	0.40	0.07	
Duration of admission <sup>4</sup>					
12 days or less	1.41	0.37	1.013	0.97	
Oxygen aids	5.28	0.001	1.36	0.53	
Mechanical ventilation	1.33	0.73	0.23	0.06	
Comorbidity					
DM	1.24	0.035	1.25	0.71	
HTN	0.59	0.51	1.02	0.97	
CVD	3.03	0.201			
Severity <sup>5</sup>					
Non severe group	1.18	0.80	2.53	0.17	
Severe group	5.28	0.001	0.32	0.60	
laboratory					
ANC	0.734	0.54	1.08	0.87	
NLR	1.34	0.47	2.61	0.031	
HB	1.5	0.26	0.87	0.72	
Platelet	0.55	0.21	0.79	0.60	

ANC: Absolute neutrophilic count, CVD: Cerebro-Vascular disease, DM: Diabetes, HB: Hemoglobin, HTN: Hypertension, NLR: Neutrophil Lymphocyte Ratio, PTSD; Post Traumatic Stress Disorder.

<sup>1</sup> reference group is age group more than 60 years.

<sup>2</sup> reference group is Widow.

<sup>3</sup> reference group is higher education.

<sup>4</sup> reference group is more than12 days.

<sup>5</sup> reference group is critical group.

*P* value is significant if < 0.05.

of anxiety and OCD were 29.5% and 28.2% respectively while the incidence of depression was 68.3% (Gellan et al., 2021). A cohort study that followed COVID-19 patients for up to 90 days showed broad-based but not uniform psychiatric effects of COVID-19. In 14 to 90 day after COVID-19 diagnosis the incidence of mental health disorders was 18% of which 5% was first diagnosed. In addition, anxiety disorders were found to be more common than mood disorders. This study, however, did not find a link between post-COVID-19 anxiety and the post-traumatic stress disorder-like picture. In addition, it was discovered that rates of insomnia were extremely high among patients, possibly due to circadian disruptions following COVID-19 infection (Taquet et al., 2021).

Regarding the severity of COVID-19 infection, the critical group had the highest percentages of the probable PTSD response and abnormal responses in anxiety and psychosis subscales. Regarding PTSD, a previous study observed an increase PTSD symptoms 3 months after suffering from a critical illness that necessitated ICU admission (Cuthbertson et al., 2004), and another research observed that 14% of patients had severe PTSD symptoms six months after a serious condition that necessitated mechanical ventilation (Girard et al., 2007). According to anxiety, a cohort study followed a patient with COVID-19 up to 90 days reported an increase in the frequency of anxiety disorders (Taquet et al., 2021). Many factors are associated with anxiety after critical illness, such as an inability to communicate, lack of family, and the removal of mechanical ventilation (Shoar et al., 2016). Regarding psychosis, many reports observed the presence of psychosis in patients with COVID19 infection (Ferrando et al., 2020; Rentero et al., 2020; Smith et al., 2020). Severance et al. discovered that patients with psychotic symptoms had significantly higher IgG levels for two coronavirus strains (HKU1 and NL63) (Severance et al., 2011).

In the present study the non-severe patients had the highest percentage in many psychiatric illnesses such as somatization, Obsessivecompulsive, depression, phobic anxiety, Anger-hostility, and paranoid ideation in compared to critical and severe group. This group was more vulnerable to psychosocial stressors as self-isolation and medication at home, self-observation for any complication that could happen to them, fear of transmission of the infection to the family, and the possibility of recurrent COVID19 infection after recovery. Furthermore, Troyer et al. propose direct infection, blood circulation, neuronal involvement, hypoxic injury, immune injury, and ACE2 binding as potential causes of coronavirus nervous system damage (Troyer et al., 2020).

CRP levels correlate with the degree of inflammation and increase parallel to the increase in the largest pneumonia lesion diameter in COVID-19 patients (Wang, 2020); this supports our findings. CRP is the least in the non-severe group. On the other hand, we reported that the p-dimer was higher in the critical group. p-dimer >2 was found in an early study to be the only factor associated with mortality in COVID-19 patients (Yao et al., 2020).

In the critical group, it was observed that ferritin level was higher compared to other studied groups. A large meta-analysis found that high ferritin levels were associated with severe conditions and adult respiratory distress syndrome (ARDS) (Cheng et al., 2020). However, Wu et al. found that ferritin was neither associated with ARDS nor severe cases of COVID-19 (Wu et al., 2020). Biological factors that overlap with mental disorders and COVID-19 infection could also be involved (Wang et al., 2021), Inflammation is one of these factors. It has been linked to the pathogenesis of depression (Beurel et al., 2020), schizophrenia (Müller, 2018), and bipolar disorder (Benedetti et al., 2020), and also the systemic manifestations of COVID-19 infection (Steardo et al., 2020).

Multivariate logistic regression had been conducted to detect possible independent predictors for various psychological disorders 6 months after COVID-19 diagnosis. Female sex was an independent predictor for anxiety, phobic -anxiety, paranoid ideation, and psychosis, in line with many previous studies where females are consistently more prevalent due to biological factors and sex hormones (Lebron-Milad and Milad, 2012).

Age as a predictor for psychiatric disorders after COVID-19 infection has variable impacts, ages less than sixty had less risk for anxiety, phobic anxiety, paranoid ideation, and OCD. In contrast, those aged less than thirty were less liable to depression. In considering the general population, many previous studies found the reduced frequency of anxiety with younger age (Flint et al., 2010; Wells et al., 2006), which could be partially explained by social believes of higher death risk in the elderly.

In considering marital status as a predictor for psychiatric disorders after COVID-19, in the present study, being married or single were the only social states significantly associated with reduced risk of paranoid ideation than the widow and divorced persons. Marriage is a form of social support associated with less liability to psychological disorders (Flint et al., 2010). Divorce rates increased with higher levels of paranoid symptoms in a sample of middle-aged adults investigated in a previous study (Disney et al., 2012).

According to our observations, educational levels are just read and write predict the development of abnormal sleep, PTSD, phobic anxiety, paranoid ideation, and psychosis. Adults' educational attainment indirectly impacts their economic resources, social status, social networks, and health behaviour, leading to special psychological impacts.

Smoking is an extensively studied predictor of psychiatric abnormalities (Dome et al., 2010), with potential explanatory models including the effects of smoking on neurotransmitters, neurobiology, respiratory health, and autonomic control (Preter and Klein, 2008). In the current study, smoking was an independent predictor for OCD. In general, OCD patients have low rates of smoking (Bejerot and Humble,

#### Table 4

Multivariate logistic regressions assessing the association between risk factors somatization, anxiety, depression, and obsessive-compulsive disorder in COVID-19 patients.

Variable	Somatization		Obsession		Depression		Anxiety	
	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value
Gender								
Female	0.907	0.84	1.134	0.794	1.757	0.263	4.404	0.004
Age (years) <sup>1</sup>								
18 - 30	0.57	0.37	0.220	0.012	0.175	0.005	0.106	0.000
31 -60	0.56	0.27	0.298	0.017	0.813	0.698	0.186	0.002
Marital status <sup>2</sup>								
Single	1.120	0.910	1.212	0.816	0.368	0.247	0.522	0.484
Married	0.650	0.642	0.810	0.785	0.264	0.102	0.414	0.315
Divorce	0.570	0.683	2.111	0.468				
Education <sup>3</sup>								
Reading and writing	2.216	0.136	0.497	0.131	0.559	0.279	0.410	0.053
Elementary school			0.652	0.542	0.308	0.204	0.500	0.376
High school	1.689	0.467	0.779	0.669	1.212	0.776	3.403	0.130
Smoking state	0.86	0.78	2.926	0.028	1.825	0.237	2.330	0.096
Duration of admission <sup>4</sup>								
12 days or less	1.14	0.72	1.175	0.660	1.035	0.927	1.611	0.196
Oxygen aids	1.4	0.48	2.039	0.122	1.747	0.238	1.343	0.546
Mechanical ventilation	4.36	0.15	2.336	0.311	1.548	0.610	1.322	0.729
Comorbidity								
DM	1.12	0.85	1.681	0.358	4.101	0.039	1.095	0.877
HTN			0.723	0.662	0.713	0.662	0.818	0.775
CVD	0.33	0.31	0.150	0.061	0.785	0.799	0.346	0.272
Severity <sup>5</sup>								
Non severe group	0.63	0.56	3.699	0.081	2.618	0.154	6.700	0.017
Severe group	0.36	0.21	1.415	0.629	1.456	0.570	3.705	0.078
laboratory								
ANC	0.860	0.780	1.744	0.207	0.625	0.317	1.252	0.631
NLR	1.593	0.259	1.498	0.275	1.295	0.531	0.940	0.875
HB	2.019	0.053	1.674	0.113	2.691	0.008	1.726	0.107
Platelet	0.604	0.298	0.830	0.635	0.766	0.531	1.211	0.644

\* ANC: Absolute neutrophilic count, CVD: Cerebro-Vascular disease, DM: Diabetes, HB: Hemoglobin, HTN: Hypertension, NLR: Neutrophil Lymphocyte Ratio, PTSD; Post Traumatic Stress Disorder.

<sup>1</sup> reference group is age group more than 60 years.

<sup>2</sup> reference group is Widow.

<sup>3</sup> reference group is higher education.

<sup>4</sup> reference group is more than12 days.

<sup>5</sup> reference group is critical group.

*p*-value is significant if <0.05.

1999). This might be due to the fear of COVID-19 infection and its complication in smoker persons who mostly have chest and lung troubles from smoking.

Oxygen aids and the need for mechanical ventilation were also included in the univariate and multivariate analysis, revealing a predictor role of the need for oxygen aids in relation to sleep abnormalities and phobic-anxiety disorders. In contrast, mechanical ventilation was only a predictor for phobic-anxiety. Using tools to increase oxygen level in patients usually associated with unpleasant experience as pain, thirst (Puntillo et al., 2010), fears of left alone, choking, fear about being out of oxygen (de Haro et al., 2019). Patients who are mechanically ventilated are unable to communicate and express their emotions verbally or validate clinicians' assessments (Campbell and Happ, 2010). Comorbid conditions as DM and HTN were evaluated in our study in relation to the severity of COVID-19 infection and as predictors for psychiatric disorders. In agreement with many studies, the non-severe group in our research had the least number of patients suffering from DM and HTN (Resnick et al., 2003; Zambanini et al., 1999). DM was an independent predictor for depression, sleep abnormalities, and phobic anxiety, and psychosis. In multiple researches, comorbid conditions were associated with increased severity, morbidity, and chronicity of depressive disorders (Rush et al., 2005). Diabetes can cause sleep disturbances as a result of the disease's adverse effects on central respiratory control (Resnick et al., 2003). Moreover, in a large study, more anxiety-depression and phobic symptoms were also associated with diabetes (Zambanini et al., 1999).

According to our results, high NLR was a predictor for PTSD and

psychosis. This is supported by a previous study in which elevated NLR predicts are associated with poor outcomes in COVID-19 patients (Bo et al., 2020; McLean et al., 2011). So, increase NLR predict the increase of severity of COVID-19 infection that consider as threated life condition which predict PTSD afterwhile.

This study has limitations; studying many factors needs a larger sample size to validate the results. Additionally, long-time assessment after COVID19 infection allows for too many confounders as psychological disorders are greatly affected by social, economic, and even private life changes. In this study.

In conclusion, according to our observations, COVID-19 infection has its unique psychological impact extending to 6 months after diagnosis. Poor sleep quality, somatization, and anxiety are the most common mental illness in post Covid19. The critical group is common associated with PTSD, anxiety, and psychosis. Being female, diabetic, having oxygen support or mechanically ventilated, and high NLR level are more vulnerable for mental illness in post COVID19.

## Funding

None.

## CRediT authorship contribution statement

Gellan K. Ahmed: Investigation, Formal analysis, Writing – original draft, Visualization. Eman M. Khedr: Conceptualization, Supervision, Project administration. Dina A. Hamad: Data curation, Visualization,

#### Table 5

Multivariate logistic regressions assessing the association between risk factors Phobic-anxiety, Paranoid ideation, and Psychosis in COVID-19 patients.

Variable	Phobic- anxiety		Paranoid ideation		Psychosi	Psychosis	
	Odds	Р	Odds	Р	Odds	Р	
	ratio	value	ratio	value	ratio	value	
Gender							
Female	3.15	0.026	3.17	0.025	3.29	0.022	
Age (years) <sup>1</sup>							
18 - 30	0.14	0.002	0.122	0.001	0.419	0.16	
31 -60	0.29	0.01	0.26	0.017	0.357	0.06	
Marital status <sup>2</sup>							
Single	0.18	0.16	0.12	0.02	0.43	0.327	
Married	0.15	0.096	0.14	0.03	0.70	0.664	
Divorce	0.66	0.77	0.57	0.62			
Education <sup>3</sup>							
Reading and writing	1.368	0.03	1.23	0.01	1.162	0.002	
Elementary school	0.953	0.947	0.64	0.55	0.37	0.265	
High school	1.09	0.881	1.05	0.92	0.433	0.899	
Smoking state	1.77	0.25	0.41	0.14	2.123	0.139	
Duration of admission <sup>4</sup>							
less than 12 days	0.97	0.95	1.14	0.72	0.952	0.89	
Oxygen aids	3.2	0.019	1.41	0.46	2.08	0.134	
Mechanical ventilation	7.9	0.05	2.6	0.33	3.35	0.222	
Comorbidity							
DM	5.89	0.007	1.67	0.40	7.48	0.005	
HTN	0.60	0.54	0.68	0.62			
CVD	2.64	0.39	1.72	0.60	0.48	0.521	
Severity <sup>5</sup>							
Non severe group	17.4	0.001	8.9	0.003	2.614	0.192	
Severe group	4.63	0.05	6.7	0.009	2.63	0.176	
laboratory							
ANC	0.82	0.65	0.79	0.60	1.9	0.173	
NLR	1.13	0.73	1.27	0.54	2.08	0.064	
HB	1.148	0.67	1.62	0.16	1.04	0.89	
Platelet	1.06	0.86	1.04	0.91	1.3	0.53	

ANC: Absolute neutrophilic count, CVD: Cerebro-Vascular disease, DM: Diabetes, HB: Hemoglobin, HTN: Hypertension, NLR: Neutrophil Lymphocyte Ratio, PTSD; Post Traumatic Stress Disorder.

<sup>1</sup> reference group is age group more than 60 years.

<sup>2</sup> reference group is Widow.

<sup>3</sup> reference group is higher education.

<sup>4</sup> reference group is more than12 days.

<sup>5</sup> reference group is critical group.

*p* value is significant if <0.05.

Investigation. **Taghreed S. Meshref:** Data curation, Visualization, Investigation. **Mustafa M. Hashem:** Methodology, Supervision, Project administration. **Mai M. Aly:** Investigation, Formal analysis, Writing – original draft, Visualization.

#### **Declaration of Competing Interest**

The authors declare no conflicts of interests.

# Acknowledgement

None

#### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.psychres.2021.114243.

#### References

- Bejerot, S., Humble, M., 1999. Low prevalence of smoking among patients with obsessive-compulsive disorder. Compr. Psychiatry 40 (4), 268–272. https://doi.org/ 10.1016/s0010-440x(99)90126-8.
- Benedetti, F., Aggio, V., Pratesi, M.L., Greco, G., Furlan, R., 2020. Neuroinflammation in bipolar depression. Front. Psychiatry 11, 71. https://doi.org/10.3389/ fpsyt 2020 0007
- Beurel, E., Toups, M., Nemeroff, C.B., 2020. The Bidirectional relationship of depression and inflammation: double trouble. Neuron 107 (2), 234–256. https://doi.org/ 10.1016/j.neuron.2020.06.002.
- Bo, H.X., Li, W., Yang, Y., Wang, Y., Zhang, Q., Cheung, T., Wu, X., Xiang, Y.T., 2020. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychol. Med. 1–2. https:// doi.org/10.1017/S0033291720000999.
- Bovin, M.J., Marx, B.P., Weathers, F.W., Gallagher, M.W., Rodriguez, P., Schnurr, P.P., Keane, T.M., 2016. Psychometric properties of the PTSD checklist for diagnostic and statistical manual of mental disorders-fifth edition (PCL-5) in veterans. Psychol. Assess. 28 (11), 1379–1391. https://doi.org/10.1037/pas0000254.
- Buysse, D.J., Reynolds, C.F., Monk, T.H., Berman, S.R., Kupfer, D.J., 1989. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 28 (2), 193–213. https://doi.org/10.1016/0165-1781(89) 90047-4.
- Campbell, G.B., Happ, M.B., 2010. Symptom identification in the chronically critically ill. AACN Adv. Crit. Care 21 (1), 64–79. https://doi.org/10.1097/ NCL0b013e3181c932a8.
- Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., Li, Y., 2020. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J. Clin. Lab. Anal. 34 (10), e23618. https://doi.org/10.1002/jcla.23618.
- Cuthbertson, B.H., Hull, A., Strachan, M., Scott, J., 2004. Post-traumatic stress disorder after critical illness requiring general intensive care. Intensive Care Med. 30 (3), 450–455. https://doi.org/10.1007/s00134-003-2004-8.
- de Haro, C., Ochagavia, A., López-Aguilar, J., Fernandez-Gonzalo, S., Navarra-Ventura, G., Magrans, R., Montanyà, J., Blanch, L., de Haro, C., López-Aguilar, J., Magrans, R., Fernández-Gonzalo, S., Gomà, G., Chacón, E., Ochagavia, A., Blanch, L., Montanya, J., Sales, B., Lena, E., Lucangelo, U., Fernández, R., Subirà, C., Albaiceta, G.M., Murias, G., Kacmarek, R.M., the Asynchronies in the Intensive Care Unit, G., 2019. Patient-ventilator asynchronies during mechanical ventilation: current knowledge and research priorities. Intensive Care Med. Exp. 7 (1), 43. https://doi.org/10.1186/s40635-019-0234-5.
- Deng, J., Zhou, F., Hou, W., Silver, Z., Wong, C.Y., Chang, O., Huang, E., Zuo, Q.K., 2021. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann. N. Y. Acad. Sci. 1486 (1), 90–111. https://doi.org/10.1111/ nyas.14506.

Derogatis, L.R., 1983. Scl-90-R: Administration, scoring and procedure manual-II for the revised version, Tawson. Clinical Psychometric Research.

- Disney, K.L., Weinstein, Y., Oltmanns, T.F., 2012. Personality disorder symptoms are differentially related to divorce frequency. J. Fam. Psychol. 26 (6), 959–965. https:// doi.org/10.1037/a0030446.
- Dome, P., Lazary, J., Kalapos, M.P., Rihmer, Z., 2010. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev. 34 (3), 295–342. https://doi. org/10.1016/j.neubiorev.2009.07.013.
- Ferrando, S.J., Klepacz, L., Lynch, S., Tavakkoli, M., Dornbush, R., Baharani, R., Smolin, Y., Bartell, A., 2020. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics 61 (5), 551–555. https://doi.org/10.1016/j.psym.2020.05.012.
- Flint, A.J., Peasley-Miklus, C., Papademetriou, E., Meyers, B.S., Mulsant, B.H., Rothschild, A.J., Whyte, E.M., Group, S.P.S., 2010. Effect of age on the frequency of anxiety disorders in major depression with psychotic features. Am. J. Geriatr. Psychiatry Off, J. Am. Assoc. Geriatr. Psychiatry 18 (5), 404–412. https://doi.org/ 10.1097/jgp.0b013e3181c294ac.
- Ahmed, G.K., Ramadan, H.K.A., Refay, S.M., Khashbah, M.A., 2021. Comparison of knowledge, attitude,socioeconomic burden, and mental health disorders of COVID-19 pandemic between general population and health care workers in Egypt. Egypt. J. Neurol., Psychiatry Neurosurg. https://doi.org/10.1186/s41983-021-00280-w in press.
- Girard, T.D., Shintani, A.K., Jackson, J.C., Gordon, S.M., Pun, B.T., Henderson, M.S., Dittus, R.S., Bernard, G.R., Ely, E.W., 2007. Risk factors for post-traumatic stress disorder symptoms following critical illness requiring mechanical ventilation: a prospective cohort study. Crit. Care 11 (1), R28. https://doi.org/10.1186/cc5708.
- Lebron-Milad, K., Milad, M.R., 2012. Sex differences, gonadal hormones and the fear extinction network: implications for anxiety disorders. Biol. Mood Anxiety Disord. 2 (1), 1–12. https://doi.org/10.1186/2045-5380-2-3.
- Li, L.Z., Wang, S., 2020. Prevalence and predictors of general psychiatric disorders and loneliness during COVID-19 in the United Kingdom. Psychiatry Res. 291, 113267–113267, doi:10.1016/j.psychres.2020.113267.
- Mak, I.W., Chu, C.M., Pan, P.C., Yiu, M.G., Chan, V.L., 2009. Long-term psychiatric morbidities among SARS survivors. Gen. Hosp. Psychiatry 31 (4), 318–326. https:// doi.org/10.1016/j.genhosppsych.2009.03.001.
- McLean, C.P., Asnaani, A., Litz, B.T., Hofmann, S.G., 2011. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J. Psychiatr. Res. 45 (8), 1027–1035. https://doi.org/10.1016/j. ipsychires.2011.03.006.
- Müller, N., 2018. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr. Bull. 44 (5), 973–982. https://doi.org/10.1093/schbul/ sby024.

Pan, K.-Y., Kok, A.A., Eikelenboom, M., Horsfall, M., Jörg, F., Luteijn, R.A., Rhebergen, D., van Oppen, P., Giltay, E.J., Penninx, B.W., 2020. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(20)30491-0.

- Preter, M., Klein, D.F., 2008. Panic, suffocation false alarms, separation anxiety and endogenous opioids. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (3), 603–612. https://doi.org/10.1016/j.pnpbp.2007.07.029.
- Puntillo, K.A., Arai, S., Cohen, N.H., Gropper, M.A., Neuhaus, J., Paul, S.M., Miaskowski, C., 2010. Symptoms experienced by intensive care unit patients at high risk of dying. Crit. Care Med. 38 (11), 2155–2160. https://doi.org/10.1097/ CCM.0b013e3181f267ee.
- Rentero, D., Juanes, A., Losada, C.P., Álvarez, S., Parra, A., Santana, V., Martí, I., Urricelqui, J., 2020. New-onset psychosis in COVID-19 pandemic: a case series in Madrid. Psychiatry Res. 290, 113097 https://doi.org/10.1016/j. psychres.2020.113097.
- Resnick, H.E., Redline, S., Shahar, E., Gilpin, A., Newman, A., Walter, R., Ewy, G.A., Howard, B.V., Punjabi, N.M., 2003. Diabetes and sleep disturbances. Find. Sleep Heart Health Study 26 (3), 702–709. https://doi.org/10.2337/diacare.26.3.702.
- Rogers, J.P., Chesney, E., Oliver, D., Pollak, T.A., McGuire, P., Fusar-Poli, P., Zandi, M.S., Lewis, G., David, A.S., 2020. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7 (7), 611–627. https://doi.org/10.1016/S2215-0366(20)30203-0.
- Rush, A.J., Zimmerman, M., Wisniewski, S.R., Fava, M., Hollon, S.D., Warden, D., Biggs, M.M., Shores-Wilson, K., Shelton, R.C., Luther, J.F., Thomas, B., Trivedi, M.H., 2005. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J. Affect. Disord. 87 (1), 43–55. https://doi.org/10.1016/j. iad.2005.03.005.
- Severance, E.G., Dickerson, F.B., Viscidi, R.P., Bossis, I., Stallings, C.R., Origoni, A.E., Sullens, A., Yolken, R.H., 2011. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr. Bull. 37 (1), 101–107. https://doi. org/10.1093/schbul/sbp052.
- Shoar, S., Naderan, M., Aghajani, M., Sahimi-Izadian, E., Hosseini-Araghi, N., Khorgami, Z., 2016. Prevalence and determinants of depression and anxiety symptoms in surgical patients. Oman Med. J. 31 (3), 176–181. https://doi.org/ 10.5001/omj.2016.35.
- Smith, C.M., Komisar, J.R., Mourad, A., Kincaid, B.R., 2020. COVID-19-associated brief psychotic disorder. BMJ Case Rep. 13 (8) https://doi.org/10.1136/bcr-2020-236940.
- Steardo, L., Steardo, L., Verkhratsky, A., 2020. Psychiatric face of COVID-19. Transl. Psychiatry 10 (1), 261. https://doi.org/10.1038/s41398-020-00949-5.
- Taquet, M., Luciano, S., Geddes, J.R., Harrison, P.J., 2021. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354

COVID-19 cases in the USA. Lancet Psychiatry 8 (2), 130–140. https://doi.org/ 10.1016/S2215-0366(20)30462-4.

- Troyer, E.A., Kohn, J.N., Hong, S., 2020. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 87, 34–39. https://doi.org/ 10.1016/j.bbi.2020.04.027.
- Wang, L., 2020. C-reactive protein levels in the early stage of COVID-19. Med. Mal. Infect. 50 (4), 332–334. https://doi.org/10.1016/j.medmal.2020.03.007.
- Wang, Q., Xu, R., Volkow, N.D., 2021. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry 20 (1), 124–130. https://doi.org/10.1002/ wps.20806.
- Worldometer COVID-19 Coronavirus Pandemic: https://www.worldometers.info/cor onavirus/ (2020). Accessed on December 12, 2020.
- Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., Schnurr, P.P., 2013. The ptsd checklist for dsm-5 (pcl-5). Scale available from the National Center for PTSD at www. ptsd.va.gov, 10.
- Wells, J.E., Browne, M.A.O., Scott, K.M., McGee, M.A., Baxter, J., Kokaua, J., Team, N.Z. M.H.S.R., 2006. Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: the New Zealand mental health survey. Aust. N. Z. J. Psychiatry 40 (10), 845–854. https://doi.org/10.1080/j.1440-1614.2006.01903.x.
- World Health Organization, 2020. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is suspected: Interim Guidance, 2020. World Health Organization, 13 March.
- Wu, C., Chen, X., Cai, Y., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180 (7), 934–943. https://doi.org/10.1001/jamainternmed.2020.0994.
- Xiang, Y.T., Yang, Y., Li, W., Zhang, L., Zhang, Q., Cheung, T., Ng, C.H., 2020. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry 7 (3), 228–229. https://doi.org/10.1016/S2215-0366(20)30046-8
- Xie, Y., Wang, Z., Liao, H., Marley, G., Wu, D., Tang, W., 2020. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect. Dis. 20 (1), 640. https://doi.org/10.1186/s12879-020-05371-2.
- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., Chen, X., Chen, S., Yu, K., Huang, Z., 2020. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J. Intensive Care 8 (1), 1–11. https://doi.org/ 10.1186/s40560-020-00466-z.
- Zambanini, A., Newson, R.B., Maisey, M., Feher, M.D., 1999. Injection related anxiety in insulin-treated diabetes. Diabetes Res. Clin. Pract. 46 (3), 239–246. https://doi.org/ 10.1016/S0168-8227(99)00099-6.